Start Your Search
P1.03 - Poster Session/ Treatment of Locoregional Disease – NSCLC (ID 212)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Locoregional Disease – NSCLC
- Presentations: 1
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
P1.03-025 - Relation of Visceral Pleura Invasion with Hilar Lymph Node Involvement and Survival in Primary Lung Cancer (ID 1328)
09:30 - 17:00 | Author(s): S. Erus
The aim of this study is to investigate the role of visceral pleura invasion on hilar lymph node involvement and survival in surgically treated primary lung cancer patients.
We examined pathological data of 219 surgically treated primary non-small cell lung cancer patients operated between january 2006 & March 2012. Patients were divided into three groups. Group 1: Patients with a tumor entrapped within the thick elastic layer (PL0), Group 2: Patients with tumor crossed the elastic layer of visceral pleura (PL1), Group 3: patients with a tumor crossed the elastic layer and reached the surface of visceral pleura (PL2). Patients with parietal pleura invasion (PL3) and operative mortality (45 patients) were excluded from the study. Groups were examined in terms of tumor size, mediastinal involvement, lymphovasculary invasionand survival.
Visceral pleura invasion (PL1 and PL2) was detected in 56 of 174 surgically treated patients (32.1%). In this group, PL1 was found in 43 patients (24.7%) and PL2 was found in 13 patients (7.4%). Mean follow-up was 48.68±27.47 months (4-106). We found that visceral pleura invasion statistically significantly reduce survival independently from hilar/mediastinal lymph node involvement (N1-N2) and tumor size (mean survival 53.78±28.91 vs 37.95±20.54 months, p=0.001). Also we found that the ratio of the presence of hilar lymph node involvement with visceral pleura invasion is statistically higher than the group without visceral pleura invasion (30.9% vs 18.1% p=0.03). There were no statistically significance in terms of survival between the groups PL1 and PL2 (mean survival 39.23±20.01 vs 33.69±22.49 p=0.39).
We should consider adjuvant treatment independently from tumor size and lymph node involvement for patients with visceral pleura invasion.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.